medicare coverage glp 1 Recent Trends in GLP-1 Use and Spending in Navigating Changes to GLP-1 Medication

What are current indications for GLP1 agonists in the context of cardiometabolic disease

It is hands-off, consistent, and produces results that are easy on digestion

Evaluated in double-blind, placebo-controlled human clinical trials and verifiable with a saliva test strip 90 minutes after your first dose

Pharmacokinetic evaluations in humans report an approximate half-life of ~1 hour following subcutaneous administration, reflecting greater stability than native -MSH while remaining suitable for controlled research observation

All this to say: Andel helps employers offer these drugs as a workplace benefit to their employees at a more affordable cost